Dr. Sarah J. McKillop
Claim this profileUniversity of Alberta Hospital
About Sarah J. McKillop
Education:
- Holds an MD (Doctor of Medicine).
- Earned an MSc (Master of Science).
Experience:
- Serves as a clinical researcher and specialist at the University of Alberta Department of Pediatrics, with ties to the Cross Cancer Institute.
- Contributed to research published in the Journal of Adolescent and Young Adult Oncology, examining the effects of the Adolescent and Young Adult Oncology Navigator program on young cancer patients' access to oncology psychosocial services.
Area of expertise
Cancer
Sarah J. McKillop has run 6 trials for Cancer. Some of their research focus areas include:
Neuroblastoma
Sarah J. McKillop has run 4 trials for Neuroblastoma. Some of their research focus areas include:
Affiliated Hospitals
University Of Alberta Hospital
Stollery Children's Hospital
Clinical Trials Sarah J. McKillop is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which is a type of protein that can bind to certain targets on the surface of cells. Inotuzumab ozogamicin is a monoclonal antibody that is linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells by binding to the CD22 protein on the surface of the cancer cell and delivering calicheamicin inside the cells to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Blinatumomab is a specialized type of monoclonal antibody known as a bispecific T-cell engager (BiTE). It works by simultaneously binding to CD19 on cancer cells and CD3 on normal immune cells, bringing them together to destroy leukemia cells. Blinatumomab is a standard part of chemo-immunotherapy treatment for B-ALL. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin or blinatumomab. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemo-immunotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first phase of therapy: Induction. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-induction treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (consolidation, blinatumomab block 1, interim maintenance 1, blinatumomab block 2, delayed intensification, interim maintenance 2, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of consolidation or part of delayed intensification. Other aims of this study include evaluating 1) side effects of treatment using patient-reported outcomes and health-related quality of life, 2) the best ways to help patients adhere to oral chemotherapy regimens, 3) the relationship between levels of inotuzumab ozogamicin in the blood and side effects, 4) the impact of chemo-immunotherapy on the immune system and risk of infection, and 5) the impact of social determinants of health on outcomes. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting
2 awards
Phase 3
Selinexor + Radiation
for Brain Cancer
This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
Recruiting
1 award
Phase 1 & 2
1 criteria
More about Sarah J. McKillop
Clinical Trial Related
6 years of experience running clinical trials · Led 30 trials as a Principal Investigator · 13 Active Clinical Trials
Treatments Sarah J. McKillop has experience with
- Cyclophosphamide
- Etoposide
- Vincristine Sulfate
- Laboratory Biomarker Analysis
- Radiation Therapy
- Cytology Specimen Collection Procedure
Breakdown of trials Sarah J. McKillop has run
Cancer
Neuroblastoma
Biphenotypic Leukemia
Burkitt's Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sarah J. McKillop specialize in?
Sarah J. McKillop focuses on Cancer and Neuroblastoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Sarah J. McKillop currently recruiting for clinical trials?
Yes, Sarah J. McKillop is currently recruiting for 13 clinical trials in Edmonton Alberta. If you're interested in participating, you should apply.
Are there any treatments that Sarah J. McKillop has studied deeply?
Yes, Sarah J. McKillop has studied treatments such as Cyclophosphamide, Etoposide, Vincristine Sulfate.
What is the best way to schedule an appointment with Sarah J. McKillop?
Apply for one of the trials that Sarah J. McKillop is conducting.
What is the office address of Sarah J. McKillop?
The office of Sarah J. McKillop is located at: University of Alberta Hospital, Edmonton, Alberta T6G 2B7 Canada. This is the address for their practice at the University of Alberta Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.